Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis-Reference-Cited by-同舟云学术

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

Published:2019-12-20 Issue:6 Volume:126 Page:1243-1252
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Palandri Francesca¹^ORCID,Breccia Massimo²^ORCID,Bonifacio Massimiliano³,Polverelli Nicola⁴,Elli Elena M.⁵,Benevolo Giulia⁶^ORCID,Tiribelli Mario⁷^ORCID,Abruzzese Elisabetta⁸^ORCID,Iurlo Alessandra⁹,Heidel Florian H.¹⁰,Bergamaschi Micaela¹¹,Tieghi Alessia¹²,Crugnola Monica¹³,Cavazzini Francesco¹⁴,Binotto Gianni¹⁵,Isidori Alessandro¹⁶,Sgherza Nicola¹⁷,Bosi Costanza¹⁸,Martino Bruno¹⁹,Latagliata Roberto²^ORCID,Auteri Giuseppe¹,Scaffidi Luigi³,Griguolo Davide⁷,Trawinska Malgorzata⁸,Cattaneo Daniele⁹,Catani Lucia¹,Krampera Mauro³,Lemoli Roberto M.¹¹,Cuneo Antonio¹⁴,Semenzato Gianpietro¹⁵,Foà Robin²,Di Raimondo Francesco²⁰,Bartoletti Daniela¹^ORCID,Cavo Michele¹,Palumbo Giuseppe A.²¹,Vianelli Nicola¹

Affiliation:

1. Institute of Hematology “L. and A. Seràgnoli” St Orsola‐Malpighi University Hospital Bologna Italy

2. Division of Cellular Biotechnology and Hematology Sapienza University Rome Italy

3. Department of Medicine Section of Hematology University of Verona Verona Italy

4. Unit of Blood Diseases and Stem Cell Transplantation Department of Clinical and Experimental Sciences University of BresciaASST-Spedali Civili di Brescia Brescia Italy

5. Hematology Division and Bone Marrow Unit San Gerardo Hospital Monza Italy

6. Division of Hematology City Hospital of Health and Science Turin Italy

7. Division of Hematology and Bone Marrow Transplantation Integrated Healthcare University of Udine Udine Italy

8. Division of Hematology St Eugene Hospital Rome Italy

9. Hematology Division Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico and University of Milan Milan Italy

10. Internal Medicine II, Hematology and Oncology Friedrich Schiller University Medical Center Jena Germany

11. Clinic of Hematology, Department of Internal Medicine IRCCS San Martino Hospital, University of Genoa Genoa Italy

12. Hematology Unit Azienda Unità Sanitaria Locale - IRCCS, Arcispedale S.Maria Nuova Reggio Emilia Italy

13. Division of Hematology University Hospital of Parma Parma Italy

14. Division of Hematology University of Ferrara Ferrara Italy

15. Unit of Hematology and Clinical Immunology University of Padua Padua Italy

16. Hematology and Stem Cell Transplantation Center Azienda Ospedaliera Ospedali Riuniti Marche Nord (AORMN) Pesaro Italy

17. Division of Hematology Home for the Relief of Suffering San Giovanni Rotondo Italy

18. Division of Hematology Local Healthcare Unit of Piacenza Piacenza Italy

19. Division of Hematology “Bianchi Melacrino Morelli” Hospital Corporation Reggio Calabria Italy

20. Division of Hematology V. Emanuele University PolyclinicUniversity of Catania Catania Italy

21. Department of Medical Science, Surgery, and Advanced Technology “G. F. Ingrassia”, University of CataniaCatania Italy

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32664

Reference35 articles.

1. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

2. The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention

3. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis

5. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements;Cancers;2024-01-25

2. Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy;Cancer;2023-12-28

3. Treatment of anemia in myelofibrosis: focusing on novel therapeutic options;Expert Opinion on Investigational Drugs;2023-12-10

4. Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis;Future Oncology;2023-11-22

5. Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable;Clinical Cancer Research;2023-11-22